Clinical Commander

Back to dossier
cardio.atrial_flutter.thyroid-related.v1PRODUCTION
cardio.atrial_flutter.thyroid-related.v1

Thyrotoxicosis-precipitated atrial flutter

cardiologyacuteadult
Hard-required inputs
0 / 16
Care setting:

Encounter flow

11/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Thyrotoxicosis-precipitated AFL = trigger-identifiable + reversible arrhythmia. Acute focus: BB-first rate control (mechanism-aware — also reduces T4→T3 conversion at high propranolol doses) + AVOID AMIODARONE (iodine load) + thionamide initiation + AC during active thyrotoxicosis even at low CHA2DS2-VASc; Long-term focus: definitive thyroid therapy (RAI vs thyroidectomy vs prolonged thionamide) — AFL usually resolves with euthyroid state

Inputs
2
Actions
0
Advance rule
Set
Advance when

Thyrotoxicosis + flutter pattern framed

Patient inputs (18)

Hyperthyroidism + AFL prevalence rises with age (~25 % >60 y); CHA2DS2-VASc + bleed risk for AC decision

Female sex = +1 CHA2DS2-VASc; F:M ≈ 4:1 for thyrotoxicosis itself; pregnancy considerations affect thionamide choice (PTU 1st trimester, methimazole 2nd/3rd)

Resting HR >100 even in NSR is hallmark; flutter HR commonly 130–180; rate control target 80–110

Baseline LFTs before thionamide initiation (methimazole + PTU both have hepatotoxicity risk; PTU > methimazole); thyrotoxicosis itself can elevate ALP; severe LFT abnormality affects DOAC vs warfarin choice

Baseline before thionamide (agranulocytosis risk 0.2–0.5 %); leukocytosis can occur in storm

Recent iodinated contrast, amiodarone exposure, kelp/iodine supplements — affects RAI eligibility (need 4–6 wk washout); jodbasedow risk in nodular goiter

Confirm flutter morphology + rate; rule out concomitant AF; QT for medication risk; check for ischemic changes (demand-ischemia possible at high rates)

TTE for LV function (often preserved or hyperdynamic in thyrotoxicosis; LV dysfunction suggests tachycardia-mediated cardiomyopathy or chronic substrate); LA size; valvular disease screen

Cornerstone diagnostic — TSH suppressed (<0.1) + elevated free T4 and/or free T3 confirms overt hyperthyroidism; T3 toxicosis pattern (T4 normal, T3 high) seen in early Graves or toxic adenoma

Rule out demand-ischemia at high rates; tachycardia-mediated injury possible; baseline before high-dose BB

SBP <90 with flutter RVR + thyrotoxicosis → DCCV or aggressive BB; high-output state may have widened pulse pressure with normal SBP but compromised CO

Hyperpyrexia ≥38.5 °C is a Burch-Wartofsky storm criterion; differentiates simple thyrotoxicosis from storm

Burch-Wartofsky Point Scale for thyroid storm severity (45+ = storm, 25–44 = impending storm, <25 = unlikely); drives ICU vs floor disposition + simultaneous storm protocol

CHA2DS2-VASc for AC indication; CRITICAL CAVEAT — thyrotoxicosis itself raises stroke risk independent of CHA2DS2-VASc, so AC is generally indicated during active thyrotoxicosis even at score 0–1 (ACC/AHA 2024 + ATA 2016 endorsement)

HAS-BLED for AC bleed-risk; warfarin dosing erratic in hyperthyroid → euthyroid transition (clotting factor metabolism shifts) — DOAC preferred

eGFR for DOAC dosing; thyrotoxicosis can transiently affect renal function via volume changes

TSI (thyroid-stimulating immunoglobulin) or TRAb to confirm Graves etiology; positive in ~95 % of Graves; guides definitive therapy choice

Thyroid ultrasound or RAIU/scan to differentiate Graves (diffuse uptake, vascular) from toxic nodule (focal uptake) from thyroiditis (low uptake) — affects definitive therapy decision

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (5)

5 need judgement
  • informationallife_threateningthyroid_storm_burch_wartofsky_45_with_aflutter
    Burch-Wartofsky Point Scale ≥45 (thyroid storm — hyperpyrexia + tachycardia + CNS dysfunction + GI/hepatic + cardiovascular) + AFL — life-threatening multisystem emergency
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningthionamide_agranulocytosis_or_hepatotoxicity
    Patient on methimazole or PTU develops fever + sore throat (agranulocytosis 0.2-0.5%) OR ALT/AST >3× ULN (hepatotoxicity, PTU > methimazole)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereamiodarone_exposure_error_in_thyrotoxicosis
    Patient with active thyrotoxicosis given amiodarone for AFL/AF rate control by team unaware of thyroid status — iodine load can precipitate or worsen storm
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereAC_bleed_during_thyrotoxicosis
    Major bleeding on AC during active thyrotoxicosis — clotting factor metabolism shifts dramatically during transition to euthyroid making INR/dose management challenging
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverepersistent_aflutter_post_euthyroid
    AFL persists or recurs despite achievement of euthyroid state on thionamide or post-definitive therapy — suggests substrate-driven flutter masquerading as thyrotoxicosis-precipitated
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RISK_STRATIFICATIONrequiredDrives risk stratification
Loading…

Recommended regimen

Thyrotoxicosis-precipitated atrial flutter — BB-first rate control (propranolol mechanism-aware) + AVOID AMIODARONE + thionamide initiation + DOAC during active thyrotoxicosis — ACC/AHA 2024 (PMID 38753446) + ATA 2016 (PMID 27521067)
axis: aflutter_thyrotoxicosis_pathway
Selected axis "Thyrotoxicosis-precipitated atrial flutter — BB-first rate control (propranolol mechanism-aware) + AVOID AMIODARONE + thionamide initiation + DOAC during active thyrotoxicosis — ACC/AHA 2024 (PMID 38753446) + ATA 2016 (PMID 27521067)" by default fallback (first axis)
  • propranolol
    first line
    beta_blocker_nonselective
    40 mg PO q4-6h (or 1 mg IV slow push q5min up to 5 mg in storm); titrate to HR 80-110 • PO/IV • q4-6h PO / titrate IV
    triggers: thyrotoxicosis_with_aflutter, thyroid_storm, symptom_palliation_needed
    PREFERRED BB in thyrotoxicosis — at high doses (≥160 mg/d) reduces peripheral T4→T3 conversion via 5'-deiodinase inhibition; rapid symptom palliation (palpitations, tremor, anxiety); ATA 2016 (PMID 27521067) Class I; ACC/AHA 2024 rate control
    rxcui 8787
  • metoprolol_tartrate
    first line
    beta_blocker_b1_selective
    5 mg IV q5min × 3 (max 15 mg) then 25-50 mg PO BID • IV/PO • IV q5min × 3 → PO BID
    triggers: propranolol_unavailable, b1_selective_preferred_eg_asthma, standard_aflutter_rate_control
    Acceptable alternative to propranolol (does not reduce T4→T3 conversion but effective rate control); ACC/AHA 2024 (PMID 38753446) Class I
    rxcui 203191
  • esmolol
    first line
    beta_blocker_b1_ultrashort
    500 mcg/kg IV bolus then 50-300 mcg/kg/min infusion • IV • continuous infusion
    triggers: hemodynamic_instability_titratable_BB_needed, thyroid_storm_titratable_control
    Ultra-short half-life (~9 min) allows rapid titration in unstable patients; useful in storm to avoid prolonged β-blockade if hemodynamics shift
    rxcui 203222
  • methimazole
    first line
    thionamide
    20-30 mg/d PO (divided BID-TID for first weeks then once daily) • PO • daily
    triggers: hyperthyroidism_definitive_thionamide_choice, non_pregnant_or_2nd_3rd_trimester
    PREFERRED thionamide — lower hepatotoxicity than PTU; once-daily dosing improves adherence; ATA 2016 (PMID 27521067) Class I; titrate to euthyroid TSH then RAI/thyroidectomy decision
    rxcui 6835
  • propylthiouracil
    comorbidity specific
    thionamide
    100 mg PO q8h (then up to 300-400 mg/d in storm) • PO • q8h
    triggers: 1st_trimester_pregnancy, thyroid_storm, methimazole_intolerance_or_allergy
    Use 1st trimester (methimazole teratogenic — aplasia cutis, choanal/esophageal atresia); preferred in storm (additionally blocks peripheral T4→T3 conversion at high doses); switch to methimazole at start of 2nd trimester; ATA 2016
    rxcui 8794
  • apixaban
    first line
    DOAC_factor_Xa
    5 mg BID (2.5 mg BID if 2 of: ≥80 yr, ≤60 kg, Cr ≥1.5) • PO • BID
    triggers: active_thyrotoxicosis_with_aflutter, cardioversion_planned_or_completed, cha2ds2vasc_>=1
    PREFERRED AC during active thyrotoxicosis — warfarin dosing erratic during hyperthyroid → euthyroid transition (clotting factor metabolism shifts dramatically); ARISTOTLE foundational (PMID 21870978); ACC/AHA 2024 (PMID 38753446) class I; thyrotoxicosis-AFL/AF generally warrants AC even at low CHA2DS2-VASc per ATA 2016 endorsement
    rxcui 1364430
  • rivaroxaban
    first line
    DOAC_factor_Xa
    20 mg with food (15 mg if CrCl 15-50) • PO • once daily
    triggers: cardioversion_planned_or_completed, apixaban_unavailable
    ROCKET-AF alternative DOAC; once-daily dosing improves adherence
    rxcui 1114195
  • warfarin
    comorbidity specific
    vitamin_K_antagonist
    5 mg daily; INR target 2-3 with WEEKLY monitoring during thyroid transition • PO • daily
    triggers: mechanical_valve, severe_renal_failure_CrCl_<15, cost_constraint
    AVOID if possible during active thyrotoxicosis — clotting factor metabolism shifts erratically; if must use, weekly INR + dose adjustments expected; transition to DOAC once euthyroid if eligible
    rxcui 11289
  • hydrocortisone
    comorbidity specific
    glucocorticoid
    100 mg IV q8h (or dexamethasone 2 mg IV q6h) • IV • q8h
    triggers: thyroid_storm, burch_wartofsky_>=45, autoimmune_graves_storm_component
    STORM PROTOCOL — blocks peripheral T4→T3 conversion via 5'-deiodinase inhibition + treats relative adrenal insufficiency of storm + suppresses Graves autoimmune component; ATA 2016 + Burch-Wartofsky
    rxcui 5492
  • cholestyramine
    comorbidity specific
    bile_acid_sequestrant
    4 g PO QID • PO • QID
    triggers: thyroid_storm, severe_thyrotoxicosis_with_enterohepatic_recycling
    STORM ADJUNCT — interrupts enterohepatic recycling of thyroid hormone; ATA 2016 IIa; useful in storm or refractory thyrotoxicosis
    rxcui 2447
  • potassium_iodide_sski
    comorbidity specific
    iodide_supplementation
    5 drops (250 mg) PO q6h, MUST start ≥1 h AFTER thionamide • PO • q6h
    triggers: thyroid_storm, preoperative_thyroidectomy_preparation
    STORM ADJUNCT — Wolff-Chaikoff effect blocks new thyroid hormone synthesis + release; CRITICAL TIMING — give ≥1 h AFTER first thionamide dose to avoid jodbasedow (substrate for synthesis); ATA 2016
    rxcui 8597

outpatient playbook — drug actions (3)

  1. 1. long-term AC reassessment
    rxcui 1364430
    apixaban 5 mg BID per CHA2DS2-VASc + euthyroid status; CONSIDER STOPPING if score 0-1 + sustained NSR + euthyroid for ≥6 mo • PO • BID
    trigger: Long-term per stroke risk + euthyroid
    ACC/AHA 2024 — AC indication is per stroke risk; once euthyroid + sustained NSR + low CHA2DS2-VASc, AC may be discontinued (individualized)
  2. 2. continue or taper BB per HR + symptoms
    rxcui 8787
    propranolol 40 mg PO q8h or metoprolol succinate 25 mg PO daily; taper if euthyroid + resting HR <80 • PO • q8h / daily
    trigger: Per HR + thyroid status
    Wean BB as euthyroid achieved
  3. 3. levothyroxine if post-RAI or post-thyroidectomy hypothyroid
    rxcui 10582
    1.6 mcg/kg/d PO daily — adjust per TSH • PO • daily
    trigger: Post-definitive therapy hypothyroidism
    Lifelong replacement after definitive therapy

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Palpitations + tachycardia + heat intolerance + tremor + weight loss + diaphoresis in patient with new-onset AFL/AF — thyrotoxicosis screen mandatory; Atrial flutter on 12-lead ECG + suppressed TSH (<0.1) + elevated free T4/T3 — thyrotoxicosis-precipitated AFL confirmed; Known Graves disease, toxic multinodular goiter, or toxic adenoma + new AFL/AF presentation.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Thyrotoxicosis-precipitated atrial flutter** (cardio.atrial_flutter.thyroid-related.v1).
Scope: Thyrotoxicosis-precipitated AFL = trigger-identifiable + reversible arrhythmia. Acute focus: BB-first rate control (mechanism-aware — also reduces T4→T3 conversion at high propranolol doses) + AVOID AMIODARONE (iodine load) + thionamide initiation + AC during active thyrotoxicosis even at low CHA2DS2-VASc; Long-term focus: definitive thyroid therapy (RAI vs thyroidectomy vs prolonged thionamide) — AFL usually resolves with euthyroid state

No severity triggers fired against current inputs.

Plan

Regimen axis: **Thyrotoxicosis-precipitated atrial flutter — BB-first rate control (propranolol mechanism-aware) + AVOID AMIODARONE + thionamide initiation + DOAC during active thyrotoxicosis — ACC/AHA 2024 (PMID 38753446) + ATA 2016 (PMID 27521067)**.
1. propranolol 40 mg PO q4-6h (or 1 mg IV slow push q5min up to 5 mg in storm); titrate to HR 80-110 PO/IV q4-6h PO / titrate IV (beta_blocker_nonselective, first line) — PREFERRED BB in thyrotoxicosis — at high doses (≥160 mg/d) reduces peripheral T4→T3 conversion via 5'-deiodinase inhibition; rapid symptom palliation (palpitations, tremor, anxiety); ATA 2016 (PMID 27521067) Class I; ACC/AHA 2024 rate control
2. metoprolol_tartrate 5 mg IV q5min × 3 (max 15 mg) then 25-50 mg PO BID IV/PO IV q5min × 3 → PO BID (beta_blocker_b1_selective, first line) — Acceptable alternative to propranolol (does not reduce T4→T3 conversion but effective rate control); ACC/AHA 2024 (PMID 38753446) Class I
3. esmolol 500 mcg/kg IV bolus then 50-300 mcg/kg/min infusion IV continuous infusion (beta_blocker_b1_ultrashort, first line) — Ultra-short half-life (~9 min) allows rapid titration in unstable patients; useful in storm to avoid prolonged β-blockade if hemodynamics shift
4. methimazole 20-30 mg/d PO (divided BID-TID for first weeks then once daily) PO daily (thionamide, first line) — PREFERRED thionamide — lower hepatotoxicity than PTU; once-daily dosing improves adherence; ATA 2016 (PMID 27521067) Class I; titrate to euthyroid TSH then RAI/thyroidectomy decision
5. propylthiouracil 100 mg PO q8h (then up to 300-400 mg/d in storm) PO q8h (thionamide, comorbidity specific) — Use 1st trimester (methimazole teratogenic — aplasia cutis, choanal/esophageal atresia); preferred in storm (additionally blocks peripheral T4→T3 conversion at high doses); switch to methimazole at start of 2nd trimester; ATA 2016
6. apixaban 5 mg BID (2.5 mg BID if 2 of: ≥80 yr, ≤60 kg, Cr ≥1.5) PO BID (DOAC_factor_Xa, first line) — PREFERRED AC during active thyrotoxicosis — warfarin dosing erratic during hyperthyroid → euthyroid transition (clotting factor metabolism shifts dramatically); ARISTOTLE foundational (PMID 21870978); ACC/AHA 2024 (PMID 38753446) class I; thyrotoxicosis-AFL/AF generally warrants AC even at low CHA2DS2-VASc per ATA 2016 endorsement
7. rivaroxaban 20 mg with food (15 mg if CrCl 15-50) PO once daily (DOAC_factor_Xa, first line) — ROCKET-AF alternative DOAC; once-daily dosing improves adherence
8. warfarin 5 mg daily; INR target 2-3 with WEEKLY monitoring during thyroid transition PO daily (vitamin_K_antagonist, comorbidity specific) — AVOID if possible during active thyrotoxicosis — clotting factor metabolism shifts erratically; if must use, weekly INR + dose adjustments expected; transition to DOAC once euthyroid if eligible
9. hydrocortisone 100 mg IV q8h (or dexamethasone 2 mg IV q6h) IV q8h (glucocorticoid, comorbidity specific) — STORM PROTOCOL — blocks peripheral T4→T3 conversion via 5'-deiodinase inhibition + treats relative adrenal insufficiency of storm + suppresses Graves autoimmune component; ATA 2016 + Burch-Wartofsky
10. cholestyramine 4 g PO QID PO QID (bile_acid_sequestrant, comorbidity specific) — STORM ADJUNCT — interrupts enterohepatic recycling of thyroid hormone; ATA 2016 IIa; useful in storm or refractory thyrotoxicosis
11. potassium_iodide_sski 5 drops (250 mg) PO q6h, MUST start ≥1 h AFTER thionamide PO q6h (iodide_supplementation, comorbidity specific) — STORM ADJUNCT — Wolff-Chaikoff effect blocks new thyroid hormone synthesis + release; CRITICAL TIMING — give ≥1 h AFTER first thionamide dose to avoid jodbasedow (substrate for synthesis); ATA 2016

Setting playbook (outpatient) — Long-term endocrinology + cardiology coordination; definitive thyroid therapy completion (RAI or thyroidectomy or sustained remission on thionamide); rhythm surveillance post-euthyroid (most resolve); long-term AC reassessment per evolving CHA2DS2-VASc + euthyroid status; ablation pathway if persistent AFL despite euthyroid
12. long-term AC reassessment apixaban 5 mg BID per CHA2DS2-VASc + euthyroid status; CONSIDER STOPPING if score 0-1 + sustained NSR + euthyroid for ≥6 mo PO BID — Long-term per stroke risk + euthyroid (ACC/AHA 2024 — AC indication is per stroke risk; once euthyroid + sustained NSR + low CHA2DS2-VASc, AC may be discontinued (individualized))
13. continue or taper BB per HR + symptoms propranolol 40 mg PO q8h or metoprolol succinate 25 mg PO daily; taper if euthyroid + resting HR <80 PO q8h / daily — Per HR + thyroid status (Wean BB as euthyroid achieved)
14. levothyroxine if post-RAI or post-thyroidectomy hypothyroid 1.6 mcg/kg/d PO daily — adjust per TSH PO daily — Post-definitive therapy hypothyroidism (Lifelong replacement after definitive therapy)

Non-pharmacologic actions:
- Sustained endocrine follow-up per definitive therapy outcome
- Lifestyle: stress management, smoking cessation (Graves orbitopathy), iodine intake moderation
- EP referral for CTI ablation candidacy if persistent typical AFL despite euthyroid (Calkins 2007 PMID 17572388 — CTI ablation curative >95% for typical)
- Family screening for autoimmune thyroid disease if Graves

AVOID / contraindication checks:
- AVOID_AMIODARONE_in_active_thyrotoxicosis — 37% iodine by weight can precipitate or worsen storm/jodbasedow (ATA 2016 PMID 27521067)
- Methimazole_teratogenic_avoid_1st_trimester_use_PTU_instead (ATA 2016)
- PTU_hepatotoxicity_higher_than_methimazole_use_only_when_indicated (ATA 2016)
- Thionamide_agranulocytosis_0.2 0.5pct_warn_patient_fever_sore_throat_immediate_CBC
- Warfarin_INR_erratic_in_hyperthyroid_transition_DOAC_preferred
- Potassium_iodide_must_start_after_thionamide_to_avoid_jodbasedow (ATA 2016)
- DOAC_renal_dose_adjustment (ESC 2024 PMID 39050851)
- Decision:AC_during_active_thyrotoxicosis_even_at_low_CHA2DS2VASc (ATA 2016 + ACC/AHA 2024 endorsement)
- Decision:DCCV_only_if_hemodynamically_unstable — flutter often refractory until euthyroid; spontaneous CV common with euthyroid
- Decision:storm_protocol_BB_+_PTU_+_iodine_after_thionamide_+_hydrocortisone_+_cholestyramine (ATA 2016)
- Decision:long_term_AC_reassessment_once_euthyroid_+_NSR_sustained_+_low_CHA2DS2VASc

Monitoring

Regimen monitoring:
- continuous telemetry during acute phase
- TFTs daily in storm then q24-48h then weekly until euthyroid
- LFT + CBC at 2 + 4 wk on thionamide then periodically (hepatotoxicity + agranulocytosis surveillance)
- INR weekly if warfarin during thyroid transition
- eGFR q3-6mo on DOAC
- echo at 3-6 mo to assess LV function recovery + LA size
- rhythm surveillance post euthyroid for AFL recurrence (Holter or smartwatch)
- AC reassessment per CHA2DS2VASc once euthyroid + NSR sustained

Setting (outpatient) monitoring:
- TFTs q3-12 mo per definitive therapy phase
- CBC + eGFR q6m on DOAC (ESC 2024 PMID 39050851)
- Holter at 6 + 12 mo for recurrence
- Annual cardiology assessment

Follow-up plan: Endocrinology q4-6 wk during thionamide titration to euthyroid; definitive therapy decision (RAI 6-12 mo of thionamide, OR thyroidectomy if large goiter/compressive symptoms/pregnancy planned/RAI-ineligible, OR continued thionamide); cardiology surveillance for AFL recurrence post-euthyroid (most resolve; ablation if persistent); long-term AC reassessment (typically discontinue once euthyroid + sustained NSR + low CHA2DS2-VASc; continue if recurrent or score ≥2)
- Close-out criterion: Endocrine + cardiology + definitive therapy + AC plan documented

Monitoring phase: 24-48 h telemetry for rhythm response to BB; daily TFTs in storm (every 24-48 h until trending normal then weekly); LFT + CBC at 2 + 4 wk on thionamide (hepatotoxicity + agranulocytosis surveillance); INR weekly if warfarin (erratic during transition); 4-wk post-CV AC adherence + bleed surveillance

Disposition

Current setting: outpatient — Long-term endocrinology + cardiology coordination; definitive thyroid therapy completion (RAI or thyroidectomy or sustained remission on thionamide); rhythm surveillance post-euthyroid (most resolve); long-term AC reassessment per evolving CHA2DS2-VASc + euthyroid status; ablation pathway if persistent AFL despite euthyroid

Disposition criteria:
- Continue chronic surveillance; cross-link to cardio.atrial_flutter.typical-cavotricuspid.v1 if typical morphology + ablation pathway; cross-link to endo chronic-hypothyroid pathway after definitive therapy

Escalation triggers (move to higher acuity):
- Recurrent flutter despite euthyroid + AC → EP for CTI ablation candidacy
- Recurrent thyrotoxicosis despite definitive therapy → endocrine reassessment
- New LV dysfunction → cardio.acute-hf.core.v1 routing
- Major bleed on AC → reverse + reassess long-term AC strategy
- Post-RAI thyroid storm (rare 5-10 d post) → emergent storm protocol

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Burch-Wartofsky Point Scale ≥45 (thyroid storm — hyperpyrexia + tachycardia + CNS dysfunction + GI/hepatic + cardiovascular) + AFL — life-threatening multisystem emergency
- [LIFE_THREATENING] Patient on methimazole or PTU develops fever + sore throat (agranulocytosis 0.2-0.5%) OR ALT/AST >3× ULN (hepatotoxicity, PTU > methimazole)
- [SEVERE] Patient with active thyrotoxicosis given amiodarone for AFL/AF rate control by team unaware of thyroid status — iodine load can precipitate or worsen storm

Citations

- 2024 ACC/AHA/ACCP/HRS AF + AFL Joint Guideline (Joglar PMID 38753446) + ESC 2024 AF (Van Gelder PMID 39050851) + 2016 ATA Hyperthyroidism Guidelines (Ross PMID 27521067) [PMID:38753446](https://pubmed.ncbi.nlm.nih.gov/38753446/)
- Cited evidence (PMID 39050851) [PMID:39050851](https://pubmed.ncbi.nlm.nih.gov/39050851/)
- Cited evidence (PMID 27521067) [PMID:27521067](https://pubmed.ncbi.nlm.nih.gov/27521067/)
- Cited evidence (PMID 17314344) [PMID:17314344](https://pubmed.ncbi.nlm.nih.gov/17314344/)
- Cited evidence (PMID 15302629) [PMID:15302629](https://pubmed.ncbi.nlm.nih.gov/15302629/)

Last reconciled with current guidelines: 2026-05-15.
References
  • 2024 ACC/AHA/ACCP/HRS AF + AFL Joint Guideline (Joglar PMID 38753446) + ESC 2024 AF (Van Gelder PMID 39050851) + 2016 ATA Hyperthyroidism Guidelines (Ross PMID 27521067) — PMID:38753446
  • Cited evidence (PMID 39050851) — PMID:39050851
  • Cited evidence (PMID 27521067) — PMID:27521067
  • Cited evidence (PMID 17314344) — PMID:17314344
  • Cited evidence (PMID 15302629) — PMID:15302629